Graft versus host disease (GVHD) Market Analysis, Market Size, Epidemiology, Companies, Drugs and Competitive Analysis by DelveInsight

Graft versus host disease (GVHD) Market Analysis, Market Size, Epidemiology, Companies, Drugs and Competitive Analysis by DelveInsight

“”Graft versus host disease (GVHD)- Market Insight, Epidemiology and Market Forecast -2030””

DelveInsight has launched a new report on “Graft versus host disease (GVHD)- Market Insight, Epidemiology and Market Forecast -2030”.

 

DelveInsight’s “Graft versus host disease (GVHD) – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Graft versus host disease (GVHD), historical and forecasted epidemiology as well as the Graft versus host disease (GVHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of the report:

  1. Based on DelveInsight’s analysis, total allogeneic HSCTs cases accounts for approximately 41.08% of total HSCTs cases, as there were XX allogeneic incident cases diagnosed in 2017, XX of which were first allogeneic HSCT (i.e., 84.83% of total allogeneic cases)..
  2. Among the EU5 countries, Germany has the highest HSCTs cases followed by France and Italy.
  3. DelveInsight estimates higher incidence of HSCTs in the United States among 7MM.

 

Key Benefits of the Report:

  1. Graft versus host disease (GVHD) Market report covers a descriptive overview and comprehensive insight of the Graft versus host disease (GVHD) epidemiology and Graft versus host disease (GVHD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. Graft versus host disease (GVHD) market report provides insights on the current and emerging therapies.
  3. Graft versus host disease (GVHD) market report provides a global historical and forecasted market covering drug outreach in 7 MM.
  4. Graft versus host disease (GVHD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Graft versus host disease (GVHD) market.

 

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-pain-market

 

Graft versus host disease (GvHD) is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when a particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.

GvHD has two types Acute GvHD and Chronic GvHD. Acute GvHD is also known as fulminant GVHD, and occurs usually in the initial 2-3 months after transplantation. While Chronic GVHD occurs around 3-4 months after the transplantation has happened, and has more diverse complications. This type affects liver, stomach, vagina, joints, lungs, gut, mouth and glands secreting mucous or saliva.

Acute GVHD is staged and graded (grade I-IV) by the number and extent of organ involvement. While Chronic GvHD is staged according to a new clinical scoring system on a four point scale (0-3) with 0 representing no involvement, 1 representing mild involvement (no significant impairment of daily living), 2 representing moderate involvement (significant impairment of daily living) and 3 representing severe impairment (major disability).

 

“According to Delveinsight, No significant difference was found in incidence of GvHD among male and female”

 

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-pain-market

 

The launch of the emerging therapies is expected to significantly impact Graft versus host disease (GvHD) treatment scenario in the upcoming years:-

Drugs covered:

  • Imbruvica
  • Temcell HS
  • Ruxolitinib
  • Itacitinib
  • Allocetra
  • ATIR101
  • CD24Fc
  • And Many Others

 

The key players in Graft versus host disease (GvHD) market are:

  • Imbruvica
  • Temcell HS
  • Incyte Corporation
  • Enlivex Therapeutics
  • Kiadis Pharma
  • OncoImmune
  • And Many Others

 

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-pain-market

 

Table of Contents:

 

1. Report Introduction

2. GvHD Market Overview at a Glance

2.1. Market Share Distribution of GvHD in 2017

2.2. Market Share Distribution of GvHD in 2030

3. Disease Background and Overview: Graft versus Host Disease (GvHD)

3.1. Introduction

3.2. Disease Types

3.3. Acute GvHD

3.4. Chronic GvHD

3.5. Grades of GvHD

3.6. Pathophysiology

3.7. Risk Factors for GVHD

3.8. Diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Population and Forecast Parameters

4.3. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations in 7MM

4.4. Diagnosed Incident Cases of aGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM– By Region

4.5. Diagnosed Incident Cases of cGvHD in Diagnosed Incident Cases of First Allogeneic HSCTs in 7MM– By Region

4.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in 7MM-2016

4.7. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in 7MM-2027

4.8. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in 7MM-2016

4.9. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in 7MM-2027

5. Epidemiology of Graft Versus Host Disease

6. United States

6.1. Assumptions and Rationale

6.2. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in United States

6.3. Diagnosed Incident Cases of Allogeneic HSCT in United States

6.4. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in US

6.5. Incident cases of aGvHD by Grades in US

6.6. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in US

6.7. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in United States

6.8. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in United States

7. EU5

7.1. Assumptions and Rationale

7.2. Germany

7.2.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Germany

7.2.2. Diagnosed Incident Cases of Allogeneic HSCT in Germany

7.2.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Germany

7.2.4. Incident cases of aGvHD by Grades in Germany

7.2.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Germany

7.2.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Germany

7.2.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Germany

7.3. France

7.3.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in France

7.3.2. Diagnosed Incident Cases of Allogeneic HSCT in France

7.3.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in France

7.3.4. Incident cases of aGvHD by Grades in France

7.3.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in France

7.3.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in France

7.3.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in France

7.4. Italy

7.4.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Italy

7.4.2. Diagnosed Incident Cases of Allogeneic HSCT in Italy

7.4.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Italy

7.4.4. Incident cases of aGvHD by Grades in Italy

7.4.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Italy

7.4.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Italy

7.4.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Italy

7.5. Spain

7.5.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Spain

7.5.2. Diagnosed Incident Cases of Allogeneic HSCT in Spain

7.5.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Spain

7.5.4. Incident cases of aGvHD by Grades in Spain

7.5.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Spain

7.5.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Spain

7.5.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Spain

7.6. United Kingdom

7.6.1. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in UK

7.6.2. Diagnosed Incident Cases of Allogeneic HSCT in UK

7.6.3. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in UK

7.6.4. Incident cases of aGvHD by Grades in UK

7.6.5. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in UK

7.6.6. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in UK

7.6.7. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in UK

8. Japan

8.1. Assumptions and Rationale

8.2. Diagnosed Incident Cases of Hematopoietic Stem Cell Transplantations (HSCTs) in Japan

8.3. Diagnosed Incident Cases of Allogeneic HSCT in Japan

8.4. Diagnosed incident cases of aGvHD in diagnosed incident cases of first allogeneic HSCTs in Japan

8.5. Incident cases of aGvHD by grades in Japan

8.6. Diagnosed incident cases of cGvHD in diagnosed incident cases of first allogeneic HSCTs in Japan

8.7. 4-Year Diagnosed Prevalent Cases of aGvHD in First Allogeneic HSCTs in Japan

8.8. 5-Year Diagnosed Prevalent Cases of cGvHD in First Allogeneic HSCTs in Japan

9. Treatment Algorithm

9.1. Guidelines and Recommendations for Treatment of GvHD

9.2. United States

9.3. Europe

9.4. Japan

10. Unmet Needs

11. Marketed Drugs

11.1.1.Imbruvica

11.1.2.Product Description

11.1.3.Regulatory Milestones

11.1.4.Advantages & Disadvantages

11.1.5.Product Profile

11.1.6.Safety and Efficacy of Imbruvica

11.1.7.Side effects of Imbruvica

11.2. Temcell HS

11.2.1.Product Description

11.2.2.Regulatory Milestones

11.2.3.Advantages & Disadvantages

11.2.4.Product Profile

11.2.5.Safety and Efficacy of Temcell HS

11.2.6.Side effects of Temcell HS

To be continued in report

12. Emerging Therapies

12.1. Key Cross Competition

13. Therapeutics

13.1. Ruxolitinib: Incyte Corporation

13.1.1.Product Description

13.1.2.Other development activities

13.1.3.Clinical Development

13.1.4.Clinical Trials Information

13.1.5.Safety and Efficacy

13.1.6.Advantages and Disadvantages

13.1.7.Product Profile

13.2. Itacitinib: Incyte Corporation

13.2.1.Product Description

13.2.2.Other development activities

13.2.3.Clinical Development

13.2.4.Clinical Trials Information

13.2.5.Safety and Efficacy

13.2.6.Advantages and Disadvantages

13.2.7.Product Profile

14. Prophylaxis

14.1. Allocetra: Enlivex Therapeutics

14.1.1.Product Description

14.1.2.Other development activities

14.1.3.Clinical Development

14.1.4.Safety and Efficacy

14.1.5.Advantages and Disadvantages

14.1.6.Product Profile

14.2. ATIR101: Kiadis Pharma

14.2.1.Product Description

14.2.2.Other development activities

14.2.3.Clinical Development

14.2.4.Clinical Trials Information

14.2.5.Safety and Efficacy

14.2.6.Advantages and Disadvantages

14.2.7.Product Profile

15. Other Promising Candidates

15.1. CD24Fc: OncoImmune

15.1.1.Product Description

15.1.2.Other development activities

15.1.3.Clinical Development

15.1.4.Clinical Trials Information

15.1.5.Safety and Efficacy

15.1.6.Product Profile

15.1.7.To be continued in report

16. Total Market Size of GvHD in 7MM

17. 7MM Market Size by Therapies

18. United States-GvHD Market

18.1. Market Outlook

18.2. US Market Size by Therapies

18.3. Total Market Size of GVHD in United States

18.4. Market Size of Prophylaxis GVHD in United States

18.5. Market Size of aGVHD in United States

18.6. Market Size of cGVHD in United States

19. EU5-GvHD Market

19.1. Market Outlook

19.2. EU5 Market Size by Therapies

19.3. Total Market Size of GVHD in EU5

19.4. Germany

19.4.1. Total Market Size of GVHD in Germany

19.4.2. Market Size of Prophylaxis GVHD in Germany

19.4.3. Market Size of aGVHD in Germany

19.4.4. Market Size of cGVHD in Germany

19.5. France

19.5.1. Total Market Size of GVHD in France

19.5.2. Market Size of Prophylaxis GVHD in France

19.5.3. Market Size of aGVHD in France

19.5.4. Market Size of cGVHD in France

19.6. Italy

19.6.1. Total Market Size of GVHD in Italy

19.6.2. Market Size of Prophylaxis GVHD in Italy

19.6.3. Market Size of aGVHD in Italy

19.6.4. Market Size of cGVHD in Italy

19.7. Spain

19.7.1. Total Market Size of GVHD in Spain

19.7.2. Market Size of Prophylaxis GVHD in Spain

19.7.3. Market Size of aGVHD in Spain

19.7.4. Market Size of cGVHD in Spain

19.8. United Kingdom

19.8.1. Total Market Size of GVHD in UK

19.8.2. Market Size of Prophylaxis GVHD in UK

19.8.3. Market Size of aGVHD in UK

19.8.4. Market Size of cGVHD in UK

20. Japan-GvHD Market

20.1. Market Outlook

20.2. Japan Market Size by Therapies

20.3. Total Market Size of GVHD in Japan

20.4. Market Size of Prophylaxis GVHD in Japan

20.5. Market Size of aGVHD in Japan

20.6. Market Size of cGVHD in Japan

21. Market Drivers

22. Market Barriers

23. Appendix

24. Report Methodology

24.1. Sources Used

25. Consulting Services

26. Disclaimer

27. About DelveInsight

 

 

Related Reports:

 

Graft versus host disease (GVHD) – Pipeline Insights, 2020

 

Graft versus host disease (GVHD) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Graft versus host disease (GVHD) market. A detailed picture of the Graft versus host disease (GVHD) pipeline landscape is provided, which includes the disease overview and Graft versus host disease (GVHD) treatment guidelines.

 

Graft versus host disease (GVHD) – Epidemiology Forecast to 2030

 

DelveInsight’s ‘Graft versus host disease (GVHD) – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Graft versus host disease (GVHD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/